Pulse Biosciences (NASDAQ:PLSE - Get Free Report) released its earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, RTT News reports. During the same quarter in the prior year, the firm posted ($0.19) earnings per share.
Pulse Biosciences Stock Performance
Shares of NASDAQ PLSE traded down $0.29 during mid-day trading on Thursday, reaching $17.43. The company had a trading volume of 274,571 shares, compared to its average volume of 200,639. Pulse Biosciences has a twelve month low of $4.24 and a twelve month high of $22.69. The stock has a market capitalization of $1.07 billion, a PE ratio of -21.52 and a beta of 1.74. The stock's 50 day moving average is $17.70 and its 200-day moving average is $14.22.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a report on Friday, September 20th.
Check Out Our Latest Stock Analysis on PLSE
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
